RxDoctor Payments DataLook up a doctor →

Clifford Baker, MD

Interventional Pain Medicine · Sun City, AZNPI 1235342775

Payments from drug & device makers

$25,300in general payments, 2019–2025

Across 885 payments — averaging $28.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$7K
  • Nevro Corp.$4K
  • Boston Scientific$3K
  • Spinal Simplicity, LLC$2K
  • Medtronic$1K
  • Biotronik NRO, Inc.$1K
  • plus $7K from 45 others

What the payments were for

  • Speaking & faculty fees$1,8487%
  • Travel & lodging$1,7147%
  • Food & beverage$21,70286%
  • Education$360%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,300 in reported general payments places this provider in the 70th percentile of 64 interventional pain medicine providers in Arizona.

See all interventional pain medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$2,591,505
Medicare patients
2,478
Services billed
113,291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen844$24,830
Xtampza ErOxycodone Myristate53$23,474
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen834$13,903
Fentanyl Citrate18$13,873
MovantikNaloxegol Oxalate22$10,911
BelbucaBuprenorphine Hcl11$9,664
Gabapentin435$7,165
Fentanyl46$6,923
Oxycodone Hcl296$5,306
Buprenorphine21$4,969
Morphine Sulfate ErMorphine Sulfate178$3,865
Morphine Sulfate112$2,607
Lidocaine23$2,416
Tramadol Hcl433$2,165
Tizanidine Hcl183$2,146

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$552$33,13864 claims
Redhill Biopharma Inc.Movantik$60$10,91122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 64 interventional pain medicine providers in Arizona.

Other interventional pain medicine in Sun City

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →